@article{252f222187514beb8155c8cca50324ee,
title = "High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B",
abstract = "There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95\% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76\% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40\% (26 of 65) achieved HBeAg loss, and 18\% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB.",
author = "Pan, \{Calvin Q.\} and Myron Tong and Kowdley, \{Kris V.\} and Hu, \{Ke Qin\} and Chang, \{Ting Tsung\} and Lai, \{Ching Lung\} and Yoon, \{Seung Kew\} and Lee, \{Samuel S.\} and David Cohen and Hong Tang and Naoky Tsai",
note = "Funding Information: Conflicts of interest These authors disclose the following: Calvin Q. Pan has received research grants from Gilead , Bristol-Myers Squibb , Novartis , Idenix , Roche , and Schering Plough and has also served as a consultant, adviser, and on speakers bureau for Gilead, Bristol-Myers Squibb, Novartis, Idenix, Roche, Schering Plough, Onyx, Three Rivers, Salix, Genentech, Vertex, and Pharmasset. Ke-Qin Hu has participated in speakers bureaus and has received grants/research support from Bristol-Myers Squibb , Gilead , and Merck . Kris V. Kowdley has received research grants/support from Bristol-Myers Squibb , Intercept , Abbott , Pharmasset , Merck , Mochida , and Conatus ; has served as a consultant for Novartis; and has also received honoraria for participation in advisory boards for Vertex, Pharmasset, Merck, and Gilead. Ching-Lung Lai received honoraria from Bristol-Myers Squibb for participation in lectures. Samuel S. Lee has participated as a consultant for Bristol-Myers Squibb, Gilead, Janssen, Merck, Novartis, Pharmasset, Roche, and Vertex; has received research support from Bristol-Myers Squibb, Gilead, Merck, Roche, Novartis, Pharmasset, and Vertex; and has been a speaker for Bristol-Myers Squibb, Gilead, Merck, and Roche. David Cohen and Hong Tang are employees of Bristol-Myers Squibb. Naoky Tsai has participated in advisory boards and speakers bureaus for Bristol-Myers Squibb and Gilead and received research grants from Bristol-Myers Squibb and Gilead . The remaining authors disclose no conflicts. Funding Information: Funding The study was funded by Bristol-Myers Squibb. ",
year = "2012",
month = sep,
doi = "10.1016/j.cgh.2012.03.016",
language = "English",
volume = "10",
pages = "1047--1050.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders",
number = "9",
}
SDG 3 良好的健康和福祉